UNSPSC 51393407: Tazifylline

This classification denotes a bronchodilator with the molecular formula C23H32N6O3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F45OX6FZWP, chemically known as 7-[2-hydroxy-3-[4-(3-phenylsulfanylpropyl)piperazin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione but generally known as tazifylline, which bears US NIH Compound Identifier 54424. Most nations schedule tazifylline under HS 29395900 and SITC 54145. As of Q4 2014, TAZIFYLLINE remains the US FDA Preferred Term for this commodity.

Tazifylline bears US NLM identifiers UMLS ID C0075869 and NCI Concept Code C96196. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CN3CCN(CC3)CCCSC4=CC=CC=C4)O.

UNSPSC 51393407 Tazifylline is a Commodity code that, in recent state and local procurement activity, primarily covers pharmaceutical products and related supply-chain services supporting community health and pharmacy benefit programs. The recent opportunities tagged under this code reveal a mismatch between the nominal code name and actual buying patterns: Seminole County, Florida is procuring naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models through a pharmacy benefit initiative. State health departments and county health agencies are the primary issuing bodies identified in recent activity. The scope of work centers on pharmaceutical procurement, delivery logistics, and pharmacy program design rather than tazifylline specifically—a signal that either the code is being applied broadly to pharmaceutical acquisitions or the code classification itself diverges from current procurement practice.

The geographic spread of recent activity includes Florida and Texas, with Texas showing exploratory activity at the state health agency level. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; responses were due July 26, 2023, on a fixed-fee basis with an initial two-year term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels—an information-gathering mechanism rather than a formal competitive solicitation, reflecting early-stage program design. Both opportunities involve state or county procurement of pharmaceuticals and pharmacy services, though neither explicitly confirms tazifylline as a line item.